+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis



Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis



Expert Opinion on PharmacoTherapy 11(9): 1459-1466



To evaluate the benefits of aspirin in people with diabetes mellitus for the primary prevention of cardiovascular disease. We searched MEDLINE and Cochrane database for randomized, controlled trials of aspirin in people with diabetes and no cardiovascular disease. Relative risks were determined using random-effects meta-analysis. Risk reduction of aspirin compared with control groups for major cardiovascular events. Six trials consisting of 7374 patients with diabetes showed no benefits of aspirin compared with non-aspirin users with regard to overall mortality, risk reduction (relative risk (RR) = 0.96, 95% CI 0.78 - 1.18, p = 0.71), major cardiovascular events (RR = 0.90, 95% CI 0.78 - 1.05, p = 0.17) and myocardial infarction (RR = 0.95, 95% CI 0.76 - 1.18, p = 0.63). Risk of major bleeding in the aspirin compared with the non-aspirin group was not significant (RR = 2.49, 95% CI 0.70 - 8.84, p = 0.16). Aspirin therapy did not reduce the risk of cardiovascular events. Existing trials were limited by small patient numbers and low cardiovascular event rates. The use of aspirin cannot be routinely recommended for primary prevention of cardiovascular events in diabetes.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055601267

Download citation: RISBibTeXText

PMID: 20429671

DOI: 10.1517/14656561003792538


Related references

Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: An updated systematic review and meta-analysis. European Journal of Preventive Cardiology 2019: 2047487319825510-2047487319825510, 2019

Aspirin for primary prevention of cardiovascular disease in patients with diabetes: A meta-analysis. Diabetes Research and Clinical Practice 120: 31-39, 2016

Primum non nocere: An updated meta-analysis on aspirin use in primary prevention of cardiovascular disease in patients with diabetes. European Journal of Preventive Cardiology 2019: 2047487319826439, 2019

Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus. Diabetes, Obesity and Metabolism 11(11): 997-1000, 2011

Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Research and Clinical Practice 87(2): 211-218, 2010

Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. American Journal of the Medical Sciences 341(1): 1-9, 2011

Updated Meta-Analysis of Aspirin in Primary Prevention of Cardiovascular Disease. American Journal of Medicine 129(5): E35-E36, 2016

Erratum. Aspirin for the Primary Prevention of Cardiovascular Events. A Systematic Review and Meta-Analysis Comparing Patients With and Without Diabetes. Diabetes Care 2009;32:2300-2306. Diabetes Care: -, 2018

Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. Plos One 9(10): E90286, 2016

Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 32(12): 2300-2306, 2010

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 339: B4531, 2009

Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabetic Medicine 34(3): 316-327, 2016

Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis. Atherosclerosis 251: 177-182, 2017

Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials. Thrombosis and Haemostasis 104(6): 1085-1088, 2011

Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 8(): 21-21, 2007